TABLE 3.
Kaplan-Meier Rates of Persistence and Time to Discontinuation Between Rivaroxaban and Other OAC Agents
| Adherence | Survival Function | Adjusted Hazard Ratios (95% CI)a | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Rivaroxaban Cohort [A] (n = 13,645) (%) | Apixaban Cohort [B] (n = 6,304) (%) | Dabigatran Cohort [C] (n = 3,360) (%) | Warfarin Cohort [D] (n = 13,366) (%) | [A] vs. [B] | [A] vs. [C] | [A] vs. [D] | |||
| Time period after index date | |||||||||
| No gap > 30 days | 3 months | 86.0 | 83.4 | 77.3 | 75.3 | 0.78 (0.72-0.84)b | 0.64 (0.59-0.70)b | 0.61 (0.57-0.65)b | |
| 6 months | 78.2 | 75.8 | 67.2 | 62.6 | 0.83 (0.78-0.89)b | 0.67 (0.62-0.71)b | 0.59 (0.56-0.63)b | ||
| 9 months | 69.3 | 68.1 | 57.8 | 51.5 | 0.88 (0.83-0.93)b | 0.70 (0.66-0.74)b | 0.61 (0.58-0.64)b | ||
| 12 months | 59.7 | 59.0 | 47.8 | 41.2 | 0.91 (0.86-0.95)b | 0.71 (0.67-0.75)b | 0.63 (0.60-0.65)b | ||
| Time period after index date | |||||||||
| No gap > 15 days | 3 months | 76.1 | 70.7 | 65.6 | 61.5 | 0.77 (0.72-0.82)b | 0.69 (0.65-0.74)b | 0.64 (0.61-0.68)b | |
| 6 months | 63.4 | 58.4 | 51.1 | 43.7 | 0.82 (0.78-0.86)b | 0.71 (0.67-0.75)b | 0.61 (0.59-0.64)b | ||
| 9 months | 51.4 | 48.3 | 39.7 | 31.9 | 0.86 (0.82-0.90)b | 0.73 (0.70-0.77)b | 0.63 (0.61-0.65)b | ||
| 12 months | 40.2 | 38.6 | 29.8 | 22.6 | 0.89 (0.86-0.93)b | 0.75 (0.71-0.78)b | 0.64 (0.62-0.67)b | ||
| Time period after index date | |||||||||
| No gap > 45 days | 3 months | 90.4 | 89.9 | 84.5 | 82.3 | 0.86 (0.78-0.95)b | 0.68 (0.61-0.75)b | 0.60 (0.56-0.65)b | |
| 6 months | 85.1 | 85.1 | 76.7 | 73.1 | 0.89 (0.82-0.97)b | 0.68 (0.62-0.74)b | 0.60 (0.56-0.64)b | ||
| 9 months | 78.0 | 79.1 | 68.6 | 63.9 | 0.95 (0.89-1.02) | 0.71 (0.66-0.76)b | 0.63 (0.59-0.66)b | ||
| 12 months | 69.9 | 71.9 | 59.0 | 54.2 | 0.98 (0.92-1.04) | 0.72 (0.68-0.77)b | 0.64 (0.61-0.68)b | ||
aCalculated using Cox’s proportional hazards model adjusting for age, gender, region, insurance type, month and year of index date, Quan-Charlson Comorbidity Index score, CHA2-DS2-VASc score, HAS-BLED score, VTE and THA/TKA at baseline, use of oral anticoagulant at baseline, number of different drug classes used at baseline, baseline total health care cost, index medication copayment, number of factors associated with nonadherence, and risk factors for bleeding and strokes.
bP ≤ 0.05.
CI = confidence interval; OAC = oral anticoagulant; THA = total hip replacement; TKA = total knee replacement; VTE = venous thromboembolism.